Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. in vivo: Mean change
(R)-JNJ-31020028 is a high-affinity, selective brain-penetrant antagonist of the neuropeptide Y Y2 receptor, with pIC50 values of 8.07, 8.22, and 8.21 for human, rat, and mouse Y2 receptors, respectively.